Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Aspirin for Primary CV Prevention in Diabetes

N Engl J Med; ePub 2018 Aug 26; ASCEND Study Collaborative Group

In adults with diabetes mellitus (DM), aspirin use prevented serious vascular events but also caused major bleeding events, a recent study found. Researchers randomly assigned adults who had diabetes but no evident cardiovascular (CV) disease to receive aspirin (100 mg daily) or matching placebo. The primary efficacy outcome was the first serious vascular event and the primary safety outcome was the first major bleeding events. Secondary outcomes included gastrointestinal tract cancer. Among the findings:

  • 15,480 participants underwent randomization.
  • During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of those in the aspirin group vs the placebo group (658 vs 743; rate ratio, 0.88).
  • Major bleeding events occurred in 314 (4.1%) participants in the aspirin group vs 245 (3.2%) in the placebo group (rate ratio, 1.29); most of the excess being gastrointestinal bleeding and other extracranial bleeding.
  • There was no significant difference between groups in the incidence of gastrointestinal tract cancer.

Citation:

The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. [Published online ahead of print August 26, 2018]. N Engl J Med. doi:10.1056/NEJMoa1804988.

This Week's Must Reads

Tdap Immunization & Neonatal Pertussis Antibodies, JAMA; 2018 Oct 9; Healy, Rench, et al

Influenza Vaccine Effectiveness During Pregnancy, Clin Infect Dis; ePub 2018 Oct 11; Thompson, et al

Vaccination Coverage & Exemption Rates in Children, MMWR; 2018 Oct 12; Mellerson, Maxwell, et al

Severe Pertussis Infections in All Age Groups, Clin Infect Dis; ePub 2018 Oct 15; Mbayei, et al

Influenza Vaccine Type Preference Among Parents, Vaccine; ePub 2018 Oct 16; Santibanez, et al

Must Reads in Cardiology

Treating Low-Risk Patients with Mild Hypertension, JAMA Intern Med; ePub 2018 Oct 29; Sheppard, et al

Concomitant DOAC-Antiplatelet Use & Bleeding Risk, Am J Med; ePub 2018 Oct 25; Douros, et al

Omega 3 Polyunsaturated Fatty Acids & Healthy Aging, BMJ; ePub 2018 Oct 17; Lai, Otto, et al

Kidney Damage Biomarkers & Incident CKD in BP Reduction, Ann Intern Med; ePub 2018 Oct 23; Zhang, et al

Excess Hypertension Risk in Black Adults, JAMA; 2018 Oct 8; Howard, Cushman, et al